Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine (PRME) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $134000.0 in Q1 2024.

• Quarterly Non-Current Deferred Tax Liability rose 74.03% year-over-year to $134000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $134000.0 (up 74.03% YoY) and the FY2022 annual result came in at $279000.0, down 95.33% from the prior year.
• Non-Current Deferred Tax Liability climbed to $134000.0 in Q1 2024, from $108000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.0 million in Q4 2021 to a low of $77000.0 in Q1 2023.
• A 4-year average of $1.2 million and a median of $206500.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 95.33% — and 2024, when it surged 74.03%.
• Tracing PRME's Non-Current Deferred Tax Liability over 4 years: stood at $6.0 million in 2021, then sank by 95.33% to $279000.0 in 2022, then sank by 61.29% to $108000.0 in 2023, then grew by 24.07% to $134000.0 in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $134000.0 (Q1 2024), $108000.0 (Q2 2023), and $77000.0 (Q1 2023), per Business Quant data.